August 2024 An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and MRD monitoring in MM patients – CCLM 2024
August 2024 M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator – CCLM 2024
December 2023 Monitoring of Systemic Light-Chain Amyloidosis patients using Mass Spectrometry (M-inSight) in serum – ASH 2023
December 2023 Multiple Myeloma MRD tracking in blood using ultra sensitive Mass Spectrometry (M-inSight) – ASH 2023
October 2023 Personalized mass spectrometry as a tool for minimal residual disease detection in the blood of myeloma patients – IMS 2023
August 2023 Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma – Cancers 2021
August 2023 Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma – Blood Adv. 2020
August 2023 Development of a Targeted MS Serum Assay To Quantify M‑Protein in the Presence of Therapeutic Monoclonal Antibodies – J Proteome Res. 2018
